Influenza Vaccine Post Allogeneic Transplant

MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?

Study Design:

This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.

Inclusion Criteria:

• Patient Population

  • HSCT recipients who are greater than 60 days post transplant.
  • Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant
  • Show neutrophil recovery, platelet count > 50,000/mm3 (may be transfused), no known disease relapse
  • No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
  • No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months

• Controls:

  • Age 18 to 50 years
  • No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
  • No flu vaccine in previous 4 months